Benefits of weight loss of 10% or more in patients with overweight or obesity: A review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35333446/
Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient...
Conclusions: Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient effects on obesity-related complications and for patients with severe obesity
Injectable semaglutide and reductions in HbA1c and weight in the real-world in people switched from alternative glucagon-like peptide 1 receptor agonists - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35322528/
The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work demonstrated differential reductions in HbA1c and weight dependent...
Conclusion: The analysis, in this research letter, demonstrates decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide – potentially...
How to reset metabolic setpoint in obesity management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35320198/
The metabolic setpoint theory is based upon the premise that there is a barohomeostatic mechanism in humans which maintains weight within a predetermined range. This is viewed as an obstacle...
Conclusion/Relevance: The metabolic setpoint theory is based upon the premise that there is a barohomeostatic mechanism in humans which maintains weight within a predetermined range. This is viewed as an obstacle to weight loss, but can also be considered an opportunity to reset the barometabolic
Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35333444/
New appetite-regulating antiobesity treatments such as semaglutide and agents under investigation such as tirzepatide show promise in achieving weight loss of 15% or more. Energy expenditure, fat oxidation, and lean...
Conclusions: We suggest that the regulatory guidelines should be revisited to focus more on the quality of weight loss and its maintenance rather than the absolute weight loss. Commitment to this research focus both from a scientific and from a regulatory point of view could signal the beginning of the next era in obesity therapies
Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35266164/
doi: 10.1111/apt.16794. Online ahead of print. 1 Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2 Spirit Medical Communications,...
Conclusions: These studies support the use of GLP-1RAs for the improvement of underlying metabolic dysfunction observed in NASH and suggest further long-term phase III trials are warranted.
-
Michelle Jardine3yrI have found GLP-1's extremely helpful in reducing patient's weight although it is not sustainable and patient followed up 6 months to 12 months thereafter did not continue to lose Show More
-
Type 2 Diabetes Connect3yrKey Points • Source: Alimentary Pharmacology and Therapeutics • Conclusion/Relevance: “These studies support the use of GLP-1RAs for the improvement of underlying metabolic dysfunction observed in NASH and suggest further Show More